bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered on Dec. 7 to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using TC BioPharm's ImmuniCAR technology.

TC BioPharm Founder and CEO Michael Leek said the partnership will initially target CD33 to treat acute myelogenous leukemia (AML)...